Testing effectiveness (Phase 2)Looking for participantsNCT07229417
What this trial is testing
IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
Who this might be right for
Metastatic Endocrine RefractoryTriple Negative Invasive Lobular Carcinoma
M.D. Anderson Cancer Center 29